Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc., a clinical-stage biotech company, has priced an upsized $500 million offering of 0.250% convertible senior notes due 2032, with an option to increase by an additional $75 million. Proceeds will be used primarily to repay existing debt and for working capital, clinical trials, commercialization, and potential acquisitions. The notes f…